摘要
Abstract
Objective To explore the application effect of Recombinant Human Interferon α1b aerosol inhalation in pediatric acute upper respiratory tract infection.Methods A total of 102 children with acute upper respiratory tract infection admitted to Qingdao Women and Children's Hospital from October 2022 to October 2023 were selected as the study objects.All the children were divided into the control group(51 cases)and the study group(51 cases)according to the odd and even number method.The control group was given routine treatment,while the study group was given routine treatment+Recombinant Human Interferon α1b aerosol inhalation.The clinical efficacy,levels of inflammatory factors,symptoms disappearance time,and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the study group was higher than that in the control group(P<0.05).After treatment,the levels of procalcitonin,C-reactive protein,and white blood cell count in both groups were decreased,and the levels in the study group were lower than those in the control group(P<0.05).The disappearance time of fever,cough,lung moist rales,and wheezing and suffocation in the study group was shorter than that in the control group(P<0.05).The total incidence of adverse reactions in the study group was lower than that in the control group(P<0.05).Conclusion The application of Recombinant Human Interferon α1b aerosol inhalation in pediatric acute upper respiratory tract infection can alleviate inflammation reactions,shorten the symptoms disappearance time,reduce adverse reactions,and has significant clinical efficacy.关键词
重组人干扰素α1b/雾化吸入/急性上呼吸道感染/炎症因子/不良反应Key words
Recombinant Human Interferon α1b/Aerosol inhalation/Acute upper respiratory tract infection/Inflammatory factor/Adverse reaction分类
医药卫生
